-
-
[1]吴传勇, 邓安梅, 仲人前.原发性胆汁性肝硬化基因易感性的研究进展[J].肝脏, 2007, 6∶207 [2]Jorge D.Ursodeoxy cholic acid inhibits induction of the human intes-tinal epithelial nitric oxide synthase[J].Hepatology, 1995, 22 (4) ∶361. [3]叶维法.临床肝胆病学[M].天津:天津科技出版社, 1983∶779-784. [4]Prince M, Chetwynd A, Newman W, et al.survid and sympton Prog-erssion in a geographically based cohort of patients with primary bili-ary cirrhosis:follow-up for up to28years[J].Castroenterology, 2002, 123 (4) ∶1044-1051. [5]Dickson ER, Grambasch PM, Fleming TR, et al.Prognosis in Prima-ry biliary cirrhosis:model for decision making[J].Hepatology, 1989, 10 (1) ∶1-7. [6]Heathcote EJ.Management of primary biliary cirrhosis.The Ameri-can Association for the study of Liver Diseases practice guidelines[J].Hepatology, 2000, 31 (4) ∶1005-1013. [7]Lazaridis KN, Gores GJ, Lindor KD.Uresodeoxy cholic acid’mechamism of action and clinical use in hepatobiliary disorders[J].Hepatol, 2001, 35∶134-146. [8]Paumgartner G, Beucerss U.Ursodoxy cholic acid in cholestatic liver disease:mechanism of acion and therapeutic use revisited[J].Hepa-tology, 2002, 36∶525-531. [9]Pares A, Caballeria L, Rodes J, et al.Long-term effects of ursode-oxycholic acid in primary biliary cirrhosis:results of a double-blind controlled multicen tric trial[J].Hepatol, 2000, 32∶561-566. [10]Poupon RE, Lindor Kn, Pares A, et al.Combined analysis of the effect of treatment with ursodeoxy cholic acid on histologic progression in primary biliary cirrhosis[J].Hepatol, 2003, 39∶12-16. [11]Verma A.Optimum does of ursodeoxy cholic acid primary biliary cirrhosis[J].Hepatol, 1999, 11∶1069-1078. [12]Angulo P, Jorgensen RA, Liada KD.Incomplete response to ursode-oxy cholic acid in primary biliary cirrhosis:is a double dosage worth-while-[J].Am J Gastroentorol, 2001, 96∶3152-3157. [13]Leuschner U.Oral budesonide and ursodeoxy cholic acid for treat-ment of primary biliary cirrhosis:Results of a prospective double-blind trial[M].Gastroenterology, 1999, 117∶918-925。 [14]Neuberger J.Liver trausplantation for primary biliary cirrhosis:Cndications and risk of recurrence[J].Hepatol, 2003, 39 (2) ∶142-148.
本文二维码
计量
- 文章访问数: 3013
- HTML全文浏览量: 6
- PDF下载量: 1051
- 被引次数: 0